Deal would add a potential treatment for cardiovascular disease to Eli Lilly's portfolio. The food giant says it will remove the dyes from products including Jell-O, Kool-Aid and Crystal Light before ...

Verve Therapeutics is a clinical-stage company developing genetic medicines for cardiovascular disease, with its lead program ...

Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular ...

Leading generic drugmakers have mixed views on President Donald Trump’s repeated threats to impose tariffs on pharmaceutical goods in a bid to push global pharma majors to shift their manufacturing ...